Drugs / ARO-ATXN2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06672445 | Dec 2024 → Dec 2026 expected | spinocerebellar ataxia type 2 | Arrowhead Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-ATXN2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672445 ↗ |
| Route | Intrathecal | “by intrathecal (IT) administration” NCT06672445 ↗ |